Eolo Pharma

Eolo Pharma is a clinical-stage, private biotechnology company pioneering novel approaches to treat obesity and metabolic disease, with a lead candidate, MVD1, in Phase 1 clinical trials in Australia. The company has a portfolio of 60 novel small molecules targeting inflammation and metabolic dysfunction. MVD1 is designed to activate creatine-dependent thermogenesis, promoting fat burning and energy expenditure without exercise. Preclinical results have been positive, and there is reported commercial interest in their patent estate. The company has received approximately $7 million in venture capital and non-reimbursable grants, primarily from regional and private investors. Their lead mechanism, creatine-dependent thermogenesis induction, is a novel biological approach distinct from existing therapies which mostly suppress appetite.